Frontiers | Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects
The efficacy and safety of modified bortezomib‐lenalidomide‐dexamethasone in transplant‐eligible patients with newly diagnosed multiple myeloma - Okazuka - 2020 - European Journal of Haematology - Wiley Online Library
Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, E | CMAR
Combination Regimens for Multiple Myeloma Show Efficacy in the Transplant-Ineligible Population, According to Dingli
Short overview on the current standard of treatment in newly diagnosed multiple myeloma | SpringerLink
Combination Regimens for Multiple Myeloma Show Efficacy in the Transplant-Ineligible Population, According to Dingli
Treatment Options for Newly Diagnosed MM - Expert Guidance: Myeloma - Module - Myeloma Therapeutic Strategies - Oncology - Clinical Care Options
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. - Abstract - Europe PMC
ESH 2nd How to Diagnose and Treat Multiple Myeloma 2019 / Twitter
PDF) Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for
Treatment Options for Newly Diagnosed MM - Expert Guidance: Myeloma - Module - Myeloma Therapeutic Strategies - Oncology - Clinical Care Options
Lipe Discusses Therapeutic Options for a Patient With Transplant-Ineligible Multiple Myeloma
Treatment Options for Newly Diagnosed MM - Expert Guidance: Myeloma - Module - Myeloma Therapeutic Strategies - Oncology - Clinical Care Options
Multiple myeloma - The Lancet
Federal Practitioner - 0918 Current Trends in MM - Current Trends in Multiple Myeloma
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022 in: Journal of the National Comprehensive Cancer Network Volume 20 Issue 1 (2022)
SWOG - S2209- VRD-Lite Vs DRd-R Vs DRd-DR - Multiple Myeloma Clinical Trials
Designing a Therapy Sequence for the Treatment of Multiple Myeloma
Pharmaceuticals | Free Full-Text | The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma | HTML
The efficacy and safety of modified bortezomib‐lenalidomide‐dexamethasone in transplant‐eligible patients with newly diagnosed multiple myeloma - Okazuka - 2020 - European Journal of Haematology - Wiley Online Library
The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple My
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate
移植非適応での多発性骨髄腫に対するRVD lite(A Phase 2 Study of Modified Lenalidomide, Bortezomib and Dexamethasone in Transplant-Ineligible Multiple Myeloma ) - はくいのてんしちゃん論文編
Combination Regimens for Multiple Myeloma Show Efficacy in the Transplant-Ineligible Population, According to Dingli
